EEElmira Ebrahimi

Elmira Ebrahimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elmira Ebrahimi has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Comprehensive Study of Head and Neck Cancer Risk Factors : Epidemiological and Genetic Perspective

    by Elmira Ebrahimi

    Une étude exhaustive des facteurs de risque du cancer de la tête et du cou : perspectives épidémiologiques et génétiques: Le carcinome épidermoïde de la tête et du cou (CÉTC) ainsi que le carcinome épidermoïde de l’œsophage, deux cancers touchant les voies aérodigestives supérieures (VADS), constituent un fardeau important pour la santé publique à l’échelle mondiale. Ces cancers se développent à travers une interaction complexe entre des expositions environnementales modifiables et des prédispositions génétiques innées. Malgré des efforts de recherche considérables, d'importantes lacunes subsistent dans la compréhension de l’effet cancérogène de la consommation d’alcool indépendamment de l’usage du tabac, ainsi que dans l’identification de nouveaux loci de susceptibilité génétique et de leurs interactions avec les facteurs de risque environnementaux. Cette thèse vise à combler ces lacunes à travers deux études complémentaires destinées à clarifier comment les déterminants liés au mode de vie et à la génétique contribuent au risque de cancer des VADS. La première partie de ce travail repose sur une étude observationnelle de grande envergure évaluant l’association entre la consommation d’alcool et l’incidence des cancers des VADS. Cette analyse s’appuie sur des données regroupées provenant de 28 études de cohorte prospectives, totalisant près de 2,4 millions de participants avec une durée médiane de suivi de 15,5 ans, au cours de laquelle 6 903 cas incidents de cancer des VADS ont été recensés. Les résultats montrent qu’un faible niveau de consommation d’alcool, environ une boisson standard par jour, augmente significativement le risque de cancer des VADS par rapport à une consommation minimale (0,1–<5 grammes par jour). Il est essentiel de souligner que cette relation dose–effet reste visible même chez les individus n’ayant jamais fumé, fournissant ainsi un argument solide en faveur du rôle indépendant de l’alcool dans le risque de cancer des VADS. Cette association se maintient pour différents types de boissons alcoolisées, bien que l’ampleur du risque varie selon le sexe, la région géographique et l’indice de masse corporelle. S’appuyant sur ces données épidémiologiques, la seconde partie de cette recherche a consisté en une étude d’association pangénomique (GWAS) menée auprès de populations d’ascendances diverses, comprenant 19 073 cas de CÉTC et 38 857 témoins. Cette étude a permis d’identifier 29 nouveaux loci de susceptibilité, dont un variant protecteur (rs78378222) situé dans la région non traduite 3′ du gène TP53. L’analyse des interactions gène–environnement a également révélé que les effets de certains variants génétiques sont modulés par l’exposition à des agents cancérogènes établis. Prises ensemble, ces études apportent des éléments de preuve convaincants que la consommation d’alcool augmente indépendamment le risque de cancer des VADS, et que la prédisposition génétique influence ce risque tant de manière directe que via son interaction avec des expositions environnementales. L’identification de nouveaux loci génétiques améliore la compréhension des mécanismes biologiques sous-jacents à la cancérogenèse des VADS et souligne l’importance de stratégies de prévention intégrées, combinant la modification des comportements à une évaluation du profil de risque génétique.

  • Open Access

    Reassessing the link between adiposity and head and neck cancer: a Mendelian randomization study

    by Fernanda Morales Berstein, Jasmine Khouja, Mark Gormley, Elmira Ebrahimi, Shama Virani, James D McKay, Paul Brennan, Tom G Richardson, Caroline L Relton, George Davey Smith, et al.

    Background: Adiposity has been associated with an increased risk of head and neck cancer (HNC). Although body mass index (BMI) has been inversely associated with HNC risk among smokers, this is likely due to confounding. Previous Mendelian randomization (MR) studies could not fully discount causality between adiposity and HNC. Hence, we aimed to revisit this using the largest genome-wide association study (GWAS) of HNC available, which has more granular data on HNC subsites. Methods: We assessed the genetically predicted effects of BMI (N=806,834), waist-to-hip ratio (WHR; N=697,734) and waist circumference (N=462,166) on the risk of HNC (N=12,264 cases) and its subsites using a two-sample MR framework. We used inverse variance weighted (IVW) MR and multiple sensitivity analyses, including multivariable MR (MVMR), to explore the direct effects of the adiposity measures on HNC, while accounting for smoking behaviour (a well-known HNC risk factor). Results: In univariable MR, higher genetically predicted BMI increased the risk of overall HNC (IVW OR = 1.17 per 1-SD higher BMI, 95% CI 1.02–1.34). However, the IVW effect was attenuated when smoking was included in the MVMR model (OR accounting for comprehensive smoking index = 0.96 per 1-SD higher BMI, 95% CI 0.80–1.15). Furthermore, we did not find a link between genetically predicted WHR (IVW OR = 1.05 per 1-SD higher WHR, 95% CI 0.89–1.24) or waist circumference and HNC risk (IVW OR = 1.01 per 1-SD higher waist circumference, 95% CI 0.85–1.21). Conclusions: Our findings suggest that adiposity does not play a major role in HNC risk. Funding: FMB was supported by a Wellcome Trust PhD studentship in Molecular, Genetic and Lifecourse Epidemiology (224982/Z/22/Z). RCR was supported by a Cancer Research UK grant (C18281/A29019). MCB is supported by a University of Bristol Vice Chancellor’s Fellowship, the British Heart Foundation (AA/18/1/34219) and the UK Medical Research Council (MC_UU_00032/5). GDS works within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00032/1). CLR was supported by the Medical Research Council (MC_UU_00011/5) and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). SV was funded by an EU Horizon 2020 grant (agreement number 825771) and NIDCR National Institutes of Dental and Craniofacial Health (R03DE030257). JK works in a unit that receives support from the University of Bristol, a Cancer Research UK grant (C18281/A29019) and the UK Medical Research Council (grant number: MC_UU_00032/7).

  • Open Access

    Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites

    by Elmira Ebrahimi, Apiwat Sangphukieo, Hanla A. Park, Valerie Gaborieau, Aida Ferreiro-Iglesias, Brenda Diergaarde, Wolfgang Ahrens, Laia Alemany, Lidia Mrb Arantes, Jaroslav Betka, et al.

    Head and neck squamous cell carcinoma (HNSCC) includes diverse cancers arising in the oral cavity, oropharynx, and larynx, with the main risk factors being environmental exposures such as tobacco, alcohol, and human papillomavirus (HPV) infection. The genetic factors contributing to susceptibility across different populations and tumour subsites remain incompletely understood. Here we show, through a genome-wide association and fine mapping study of over 19,000 HNSCC cases and 38,000 controls from multiple ancestries, 18 genetic risk variants and 11 signals from fine mapping of the human leukocyte antigen (HLA) region, all previously unreported. rs78378222, a regulatory variant for TP53 is associated with a 40% reduction in overall HNSCC risk. We also identify gene-environment interactions, with BRCA2 and ADH1B variants showing effects modified by smoking and alcohol use. Subsite-specific analysis of the HLA region reveals distinct immune-related associations across HPV-positive and HPV-negative tumours. These findings refine the genetic architecture of HNSCC and highlight mechanisms linking inherited variation, immunity, and environmental exposures.


  • Alcohol consumption and upper aerodigestive tract squamous cell carcinoma: evidence from 28 prospective cohorts

    by Elmira Ebrahimi, Sabine Naudin, Niki Dimou, Ana-Lucia Mayén, Molin Wang, Christian C Abnet, Agneta Åkesson, Matthew J Barnett, Rino Bellocco, Amy Berrington de Gonzalez, et al.

    Background: This study aimed to investigate the association between alcohol consumption and squamous cell cancers of the upper aerodigestive tract (UADT), using data from 28 cohorts within the Pooling Project of Prospective Studies of Diet and Cancer (DCPP). Methods: Individual-level data from 2 365 437 participants were pooled. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox models to quantify the association between alcohol consumption (g/day) and UADT cancer risk, adjusting for potential confounders. Analyses were conducted by sex, smoking status, geographic region, and alcoholic beverages. Results: Over a median follow-up of 15.5 years, 6903 UADT cancer cases were identified. Alcohol consumption was positively associated with UADT cancer risk overall. Even at intakes as low as 5–<15 g/day, the HR estimate was 1.12 (95% CI = 1.03 to 1.21) compared with the reference group (0.1-<5 g/day). The HR10 g/day (95% CI) was 1.16 (1.14 to 1.18) for women and 1.12 (1.11 to 1.13) for men (Pheterogeneity < .0001). HR10 g/day estimates were 1.14 (1.13 to 1.15) in current, 1.10 (1.09 to 1.12) in former, and 1.15 (1.12 to 1.18) in never smokers. Consistent UADT HR10 g/day estimates were observed across all beverage types. HR10 g/day estimates varied across geographic regions, with HR10 g/day (95% CI) equal to 1.15 (1.14 to 1.17) in Europe–Australia, 1.13 (1.11 to 1.15) in Asia, and 1.11 (1.09 to 1.12) in North America (Pheterogeneity < .0001). Conclusion: Alcohol consumption was associated with UADT cancer risk, irrespective of smoking status or beverage type. However, due to differential baseline risks, alcohol is expected to impact the UADT cancer burden more in smokers than never smokers. These findings support public health strategies to reduce alcohol consumption.


  • Open Access

    Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention

    by James Yarmolinsky, Matthew A Lee, Evelyn Lau, Ferran Moratalla-Navarro, Emma E Vincent, Ruifang Li-Gao, Patrick C N Rensen, Ko Willems van Dijk, Kostas K Tsilidis, Apiwat Sangphukieo, et al.

    Background: The role of lipid-perturbing medications in cancer risk is unclear. Methods: We employed cis-Mendelian randomization and colocalization to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). We triangulated findings using pre-diagnostic protein measures in prospective analyses in EPIC (977 colorectal cancer cases, 4080 sub-cohort members) and the UK Biobank (860 colorectal cancer cases, 50 177 controls). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p. E40K loss-of-function variant on differential gene expression in normal colon tissue in BarcUVa-Seq. Finally, we evaluated the association of colon tumor ANGPTL4 expression with cancer-specific mortality in TCGA. Results: In analysis of 78 473 cases and 107 143 controls, genetically proxied circulating ANGPTL4 inhibition was associated with reduced colorectal cancer risk (ORSD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10−4, PPcolocalization = 0.83). This association was replicated using pre-diagnostic circulating ANGPTL4 concentrations in EPIC (hazard ratio [HR]log10 decrease = 0.91, 95% CI = 0.84 to 0.98, P = .01) and the UK Biobank (HRSD decrease = 0.93, 95% CI = 0.86 to 0.99, P = .03). In gene-set enrichment analysis of differential gene expression in 445 colon tissue samples, ANGPTL4 loss-of-function down-regulated several cancer-related biological pathways (PFDR < .05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 tumor expression was associated with reduced colorectal cancer-specific mortality risk (HRlog2 decrease = 0.66, 95% CI = 0.50 to 0.87, P = 2.92 × 10−3). Conclusions: Our integrative proteogenomic and observational analyses suggest a potential protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4 as a therapeutic target for colorectal cancer prevention.


  • The NCCN Criterion “Young Age at Onset” Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population

    by Elmira Ebrahimi, Erin Sellars, Reza Shirkoohi, Iraj Harirchi, Reza Ghiasvand, Elham Mohebbi, Kazem Zendehdel, Mohammad R. Akbari

    Because the contribution of genetic factors to the burden of breast cancer is not well investigated in Iran, we aimed to examine the prevalence of mutations in breast cancer susceptibility genes, BRCA1/2 and PALB2, and to investigate the predictive potential of hereditary breast cancer risk criteria for genetic testing in Iranian population. Next-generation sequencing was conducted on a population consisting of 299 and 125 patients with breast cancer, with and without hereditary cancer risk criteria for genetic testing, respectively. The pathogenic mutation frequency rate was 10.7% in patients with hereditary cancer criteria versus 1.6% in no criteria group (P = 0.0017). None of the 107 tested patients with only young age at onset (<40) criterion had a pathogenic mutation. Patients who had only a single heritable risk criterion [OR, 6.15; 95% confidence interval (CI), 1.26–58.59; P = 0.009] and patients with multiple heritable risk criteria (OR, 22.5; 95% CI, 5.19–201.31; P < 0.0001) had higher probabilities of carrying a mutation compared with no criteria group. Our results showed that young age at onset alone is not an indicator of hereditary breast cancer at least in the Iranian population. This is while women with multiple hereditary breast cancer risk criteria were enriched for BRCA1/2 mutations. Given such high risk of identification of a disease-causing mutation, multiple hereditary criteria should be regarded as a strong predictor for a hereditary breast cancer syndrome. These findings are important concerning the optimization of genetic counseling and furthermore establishing criteria for BRCA1/2 testing of the Iranian population.


  • Open Access

    The first successful application of preimplantation genetic diagnosis for hearing loss in Iran

    by Alireza Karimi Yazdi, Elham Davoudi-Dehaghani, Mahtab Rabbani Anari, Paanti Fouladi, Elmira Ebrahimi, Solmaz Sabeghi, Ali Eftekharian, Kiyana Sadat Fatemi, Hamed Emami, Zohreh Sharifi, et al.

    The first successful application of preimplantation genetic diagnosis for hearing loss in Iran